Alvaro Humberto Borges

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8148452/publications.pdf

Version: 2024-02-01

39 papers

1,346 citations

16 h-index 35 g-index

39 all docs 39 docs citations

39 times ranked

2427 citing authors

#	Article	IF	CITATIONS
1	Severity of Cardiovascular Disease Outcomes Among Patients With HIV Is Related to Markers of Inflammation and Coagulation. Journal of the American Heart Association, 2014, 3, e000844.	1.6	184
2	Predicting risk of cancer during HIV infection. Aids, 2013, 27, 1433-1441.	1.0	158
3	Factors Associated With Plasma IL-6 Levels During HIV Infection. Journal of Infectious Diseases, 2015, 212, 585-595.	1.9	145
4	Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. Lancet Respiratory Medicine,the, 2019, 7, 951-963.	5.2	99
5	Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection. Journal of Infectious Diseases, 2016, 214, 408-416.	1.9	94
6	Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort. Aids, 2018, 32, 2405-2416.	1.0	83
7	Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection. Clinical Infectious Diseases, 2016, 63, 1668-1676.	2.9	76
8	Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort. Clinical Infectious Diseases, 2017, 64, 1413-1421.	2.9	66
9	Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk. Current Opinion in HIV and AIDS, 2014, 9, 34-40.	1.5	64
10	Factors Associated with D-Dimer Levels in HIV-Infected Individuals. PLoS ONE, 2014, 9, e90978.	1.1	60
11	Infectionâ€related and â€unrelated malignancies, <scp>HIV</scp> and the aging population. HIV Medicine, 2016, 17, 590-600.	1.0	37
12	Combination antiretroviral therapy and cancer risk. Current Opinion in HIV and AIDS, 2017, 12, 12-19.	1.5	31
13	When to start antiretroviral therapy: the need for an evidence base during early HIV infection. BMC Medicine, 2013, 11, 148.	2.3	30
14	Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. Aids, 2014, 28, 1791-1796.	1.0	25
15	Prophylactic Platelets in Dengue: Survey Responses Highlight Lack of an Evidence Base. PLoS Neglected Tropical Diseases, 2012, 6, e1716.	1.3	19
16	Serious Non-AIDS Conditions in HIV: Benefit of Early ART. Current HIV/AIDS Reports, 2018, 15, 162-171.	1.1	16
17	The extent of Bâ€cell activation and dysfunction preceding lymphoma development in <scp>HIV</scp> â€positive people. HIV Medicine, 2018, 19, 90-101.	1.0	14
18	Classification of death causes after transplantation (CLASS). Medicine (United States), 2018, 97, e11564.	0.4	14

#	Article	IF	Citations
19	Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor–based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials. Clinical Infectious Diseases, 2016, 63, 268-280.	2.9	13
20	The Effect of Interrupted/Deferred Antiretroviral Therapy on Disease Risk: A SMART and START Combined Analysis. Journal of Infectious Diseases, 2019, 219, 254-263.	1.9	13
21	Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, 806-817.	0.9	13
22	Pyomyositis in the upper Negro river basin, Brazilian Amazonia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2012, 106, 532-537.	0.7	12
23	Cancer during HIV infection. Apmis, 2020, 128, 121-128.	0.9	12
24	Determinants of IL-6 levels during HIV infection. Journal of the International AIDS Society, 2014, 17, 19482.	1.2	10
25	Independent Association of Interleukin 6 With Low Dynamic Lung Function and Airflow Limitation in Well-Treated People With Human Immunodeficiency Virus. Journal of Infectious Diseases, 2021, 223, 1690-1698.	1.9	10
26	Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. Aids, 2014, 28, 2565-2571.	1.0	9
27	Fraction of Exhaled Nitric Oxide Levels Are Elevated in People Living With Human Immunodeficiency Virus Compared to Uninfected Controls, Suggesting Increased Eosinophilic Airway Inflammation. Clinical Infectious Diseases, 2020, 71, 3214-3221.	2.9	9
28	Predictive Value of Prostate Specific Antigen in a European HIV-positive Cohort: Does One Size Fit All?. Antiviral Therapy, 2016, 21, 529-534.	0.6	8
29	In silico thrombin generation: Plasma composition imbalance and mortality in human immunodeficiency virus. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 708-717.	1.0	8
30	Independent Associations of Tumor Necrosis Factor-Alpha and Interleukin-1 Beta With Radiographic Emphysema in People Living With HIV. Frontiers in Immunology, 2021, 12, 668113.	2.2	7
31	<scp>HIV</scp> infection is independently associated with a higher concentration of alphaâ€⁴ antitrypsin. HIV Medicine, 2018, 19, 745-750.	1.0	3
32	Predictive value of prostate-specific antigen for prostate cancer: a nested case-control study in EuroSIDA. Journal of the International AIDS Society, 2014, 17, 19510.	1.2	1
33	When is the best time to initiate antiretroviral therapy?. Lancet HIV, the, 2015, 2, e312-e313.	2.1	1
34	Editorial: HIV and Viral Co-infections. Frontiers in Microbiology, 2021, 12, 731337.	1.5	1
35	Disseminated Mycobacterium abscessus infection in an AIDS patient. Revista Da Sociedade Brasileira De Medicina Tropical, 2011, 44, 265-265.	0.4	1
36	536Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs) Comparing Initial Non-Nucleoside Reverse-Transcriptase Inhibitor (NNRTI)- versus Ritonavir Boosted Protease Inhibitor (PI/r)-based Anti-Retroviral Therapy (ART). Open Forum Infectious Diseases, 2014, 1, S20-S21.	0.4	0

#	Article	IF	CITATIONS
37	Thrombocytopenia and cancer risk during HIV infection. Aids, 2015, 29, 1425-1427.	1.0	O
38	Reply to Meijide et al. Clinical Infectious Diseases, 2017, 64, 389-390.	2.9	0
39	Classification of Death Causes after Transplantation (CLASS): Evaluation of Methodology and Initial Results. Open Forum Infectious Diseases, 2017, 4, S703-S703.	0.4	O